UBS Group Has Lowered Expectations for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE - Free Report) had its price target cut by UBS Group from $25.00 to $23.00 in a research note published on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Evercore ISI initiated coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective for the company. Bank of America lowered their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, July 15th. Barclays lowered their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Tuesday, July 15th. Citigroup decreased their target price on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. Finally, Redburn Atlantic initiated coverage on shares of Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price for the company. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $24.71.

Kenvue Price Performance

NYSE KVUE traded up $0.15 on Thursday, reaching $22.00. The company's stock had a trading volume of 12,727,162 shares, compared to its average volume of 16,312,363. The firm has a market cap of $42.21 billion, a PE ratio of 40.00, a price-to-earnings-growth ratio of 3.43 and a beta of 0.83. The business has a 50-day moving average price of $22.15 and a 200 day moving average price of $22.30. Kenvue has a 52 week low of $17.85 and a 52 week high of $25.17. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same period in the previous year, the business earned $0.28 earnings per share. The company's revenue for the quarter was down 3.9% compared to the same quarter last year. Sell-side analysts expect that Kenvue will post 1.14 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Kenvue by 4.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock valued at $2,545,000 after purchasing an additional 4,034 shares during the last quarter. Starboard Value LP purchased a new stake in shares of Kenvue in the fourth quarter valued at about $467,864,000. TrueMark Investments LLC raised its holdings in shares of Kenvue by 9.3% in the fourth quarter. TrueMark Investments LLC now owns 190,595 shares of the company's stock valued at $4,069,000 after purchasing an additional 16,161 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in shares of Kenvue in the first quarter valued at about $413,000. Finally, Cooper Investors PTY Ltd. raised its holdings in shares of Kenvue by 39.7% in the first quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company's stock valued at $20,577,000 after purchasing an additional 244,043 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.